Vertex Pharmaceuticals Inc., of Boston, said it received a complete response letter from the FDA for its supplemental new drug application (sNDA) for the use of Kalydeco (ivacaftor) in people with cystic fibrosis (CF), ages 2 and older, who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.